(NYSE: ABBV) Abbvie's forecast annual revenue growth rate of 9.53% is forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 8.52%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.4%.
Abbvie's revenue in 2026 is $59,644,000,000.On average, 31 Wall Street analysts forecast ABBV's revenue for 2026 to be $120,418,984,516,688, with the lowest ABBV revenue forecast at $113,646,366,606,864, and the highest ABBV revenue forecast at $126,353,862,110,944. On average, 26 Wall Street analysts forecast ABBV's revenue for 2027 to be $129,936,350,760,008, with the lowest ABBV revenue forecast at $121,262,026,986,152, and the highest ABBV revenue forecast at $137,714,610,525,440.
In 2028, ABBV is forecast to generate $138,225,384,684,088 in revenue, with the lowest revenue forecast at $127,633,448,584,512 and the highest revenue forecast at $147,797,539,851,000.